Literature DB >> 21895962

Increased tissue factor pathway inhibitor activity is associated with myocardial infarction in young women: results from the RATIO study.

K Winckers1, B Siegerink, C Duckers, L F Maurissen, G Tans, E Castoldi, H M H Spronk, H Ten Cate, A Algra, T M Hackeng, F R Rosendaal.   

Abstract

BACKGROUND: The tissue factor pathway inhibitor (TFPI)/protein S anticoagulant system is a potent inhibitor of blood coagulation. TFPI and protein S are major determinants of thrombin generation (TG) tests determined at low tissue factor (TF) and at high TF concentrations in the presence of activated protein C (APC). Both TFPI and protein S protect against venous thrombosis, but the importance of the TFPI/protein S system in arterial thrombosis remains unclear.
OBJECTIVES: To investigate the influence of the TFPI/protein S anticoagulant system on the risk of myocardial infarction (MI) in young women.
METHODS: The RATIO study is a case-control study in women under 50 years of age, including 205 patients and 638 controls. TFPI and protein S were quantified using ELISA. The TFPI/protein S activity (nTFPIr) and the APC sensitivity ratio (nAPCsr) were determined using TG tests. Odds ratios (ORs) adjusted for putative confounders and corresponding 95% confidence intervals (95% CI) were determined.
RESULTS: Women with MI had higher TFPI levels than controls (135.9 ± 40% vs. 124.2 ± 41%), resulting in increased TFPI/protein S activities and increased APC sensitivity. Furthermore, an increased TFPI activity was associated with MI [nTFPIr: adjusted OR Q1 vs. Q4 = 2.1 (95%CI 1.1-4.1)]. Additionally, an increased APC sensitivity was associated with MI [nAPCsr: adjusted OR Q1 vs. Q4 = 1.7 (95% CI 0.9-3.2)]
CONCLUSION: Women with MI had increased TFPI levels compared with controls. Consequently, the TFPI/protein S activity and APC sensitivity are increased in women with MI. Whether this increase in TFPI activity acts as a compensating mechanism for an increased procoagulant state or is a marker of endothelial damage remains to be investigated.
© 2011 International Society on Thrombosis and Haemostasis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21895962     DOI: 10.1111/j.1538-7836.2011.04497.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  8 in total

1.  Levels of TAFI, TFPI and ADAMTS-13 in inflammatory bowel disease.

Authors:  Bilgehan Yüzbaşıoğlu; Müge Ustaoğlu; Şule Yüzbaşıoğlu; Ulaş Emre Akbulut; Kamil Özdil
Journal:  Turk J Gastroenterol       Date:  2019-12       Impact factor: 1.852

2.  Single nucleotide polymorphisms in an intergenic chromosome 2q region associated with tissue factor pathway inhibitor plasma levels and venous thromboembolism.

Authors:  J Dennis; V Truong; D Aïssi; A Medina-Rivera; S Blankenberg; M Germain; M Lemire; L Antounians; M Civelek; R Schnabel; P Wells; M D Wilson; P-E Morange; D-A Trégouët; F Gagnon
Journal:  J Thromb Haemost       Date:  2016-09-17       Impact factor: 5.824

3.  Tissue Factor Pathway Inhibitor, Activated Protein C Resistance, and Risk of Coronary Heart Disease Due To Combined Estrogen Plus Progestin Therapy.

Authors:  Karen C Johnson; Aaron K Aragaki; Rebecca Jackson; Alex Reiner; Per Morten Sandset; Jan Rosing; Anders E A Dahm; Frits Rosendaal; JoAnn E Manson; Lisa W Martin; Simin Liu; Lewis H Kuller; Mary Cushman; Jacques E Rossouw
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-12-17       Impact factor: 8.311

4.  Thrombin generation in the Glasgow Myocardial Infarction Study.

Authors:  Machiel Smid; Arne W J H Dielis; Henri M H Spronk; Ann Rumley; Rene van Oerle; Mark Woodward; Hugo ten Cate; Gordon Lowe
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

5.  Statistical and machine learning methods for analysis of multiplex protein data from a novel proximity extension assay in patients with ST-elevation myocardial infarction.

Authors:  Emil Maag; Archana Kulasingam; Erik Lerkevang Grove; Kamilla Sofie Pedersen; Steen Dalby Kristensen; Anne-Mette Hvas
Journal:  Sci Rep       Date:  2021-07-02       Impact factor: 4.379

6.  Markers of hypercoagulability in CAD patients. Effects of single aspirin and clopidogrel treatment.

Authors:  Vibeke Bratseth; Alf-Åge Pettersen; Trine B Opstad; Harald Arnesen; Ingebjørg Seljeflot
Journal:  Thromb J       Date:  2012-08-10

7.  Thrombin Generation and Atherothrombosis: What Does the Evidence Indicate?

Authors:  Hugo Ten Cate; H Coenraad Hemker
Journal:  J Am Heart Assoc       Date:  2016-08-08       Impact factor: 5.501

8.  Non-severe COVID-19 is associated with endothelial damage and hypercoagulability despite pharmacological thromboprophylaxis.

Authors:  Sarah Kelliher; Luisa Weiss; Sarah Cullivan; Ellen O'Rourke; Claire A Murphy; Shane Toolan; Áine Lennon; Paulina B Szklanna; Shane P Comer; Hayley Macleod; Ana Le Chevillier; Sean Gaine; Kate M A O'Reilly; Brian McCullagh; John Stack; Patricia B Maguire; Fionnuala Ní Áinle; Barry Kevane
Journal:  J Thromb Haemost       Date:  2022-02-13       Impact factor: 16.036

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.